Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan.

about

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan.

Item

http://www.wikidata.org/entity/Q47148150

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Safety and Effectiveness of Na ...... rketing Surveillance in Japan.

@en

Safety and Effectiveness of Na ...... rketing Surveillance in Japan.

@nl

type

Item

label

Safety and Effectiveness of Na ...... rketing Surveillance in Japan.

@en

Safety and Effectiveness of Na ...... rketing Surveillance in Japan.

@nl

prefLabel

Safety and Effectiveness of Na ...... rketing Surveillance in Japan.

@en

Safety and Effectiveness of Na ...... rketing Surveillance in Japan.

@nl

P1476

Safety and Effectiveness of Na ...... rketing Surveillance in Japan.

@en

P2093

Haruki Makioka

http://www.w3.org/2001/XMLSchema#string

Kazumasa Yokoyama

http://www.w3.org/2001/XMLSchema#string

Masakazu Hase

http://www.w3.org/2001/XMLSchema#string

Ryusuke Sato

http://www.w3.org/2001/XMLSchema#string

Shinichi Torii

http://www.w3.org/2001/XMLSchema#string

Takahiko Saida

http://www.w3.org/2001/XMLSchema#string

Yan Ling

http://www.w3.org/2001/XMLSchema#string

Yukihiko Iizuka

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

SNP-based analysis of the HLA locus in Japanese multiple sclerosis patients.

Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

P2888

s40120-017-0084-6

P304

197-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40120-017-0084-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29119538

http://www.w3.org/2001/XMLSchema#string

P932

5700906

http://www.w3.org/2001/XMLSchema#string